Video Library

In this last batch of the Q&A Session of Blood Cancer OncTalk, Drs. Aaron Goodman, Sridevi Rajeeve, Tycel Phillips, Alakrita Taneja, and Marco Ruiz come together to answer questions from the attendees at our Blood Cancer OncTalk 2023 live event. To watch the complete playlist click here.

In this first batch of the Q&A Session of Blood Cancer OncTalk, Drs. Aaron Goodman, Sridevi Rajeeve, Tycel Phillips, Alakrita Taneja, and Marco Ruiz come together to answer questions from the attendees at our Blood Cancer OncTalk 2023 live event. To watch the complete playlist click here.

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Emerging Molecular Targets For Advanced Non-Small Cell Lung Cancer (NSCLC)

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Alankrita Taneja defines Smoldering Multiple Myeloma (SMM) and discusses how it differs from Multiple Myeloma (MM), risk factors and treatments. To watch the complete playlist click here.

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Sridevi Rajeeve gives a brief description of multiple myeloma, and how immunotherapy is used in treatment. To watch the complete playlist click here.

This is the first batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Tycel Phillips discusses Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab Glofitamab To watch the complete playlist click here.

This is the second batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Marco Ruiz explains the concept of bone marrow transplant, and how it is used in treating blood cancers. Myeloma Lymphoma To watch the complete playlist click here.

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Sridevi Rajeeve gives a brief description of multiple myeloma, and how immunotherapy is used in treatment. To watch the complete playlist click here.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.

Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.